Avalyn Pharmaceuticals
Phase 2Avalyn is a clinical-stage biotech company developing inhaled therapies to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.
Market Cap
Private
Pipeline
2
drug candidates
Patents
—
Publications
—
Private Company
Total funding raised: $450M
About
Avalyn is a clinical-stage biotech company developing inhaled therapies to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.
Small Molecules
Pipeline
22 drugs in pipeline
| Drug | Indication | Stage | Watch |
|---|---|---|---|
| AP01 | Progressive Pulmonary Fibrosis | Phase 2 | |
| AP02 + Placebo | Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 |
Funding History
4Total raised:$450M
Series B$175MJan 15, 2024
Series B$175MOct 15, 2023
Series A$50MJun 15, 2021
Series A$50MJun 15, 2021